A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Eli Lilly is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk being its biggest challenger. Over the past six months, Eli Lilly has earned significant wins ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most ...

ETFs like the VanEck Pharmaceutical ETF (PPH 0.61%) contain shares of the two leaders in the GLP-1 space right now, Eli Lilly and Novo Nordisk. Related investing topics.

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger. Over the past six months, Eli Lilly has ...